Sign In
Buy BMRN
$54.66
+1.34 (+2.51%)
At Close: Jun 03, 2026
BioMarin's First-Quarter Earnings & Sales Beat Estimates
02:25pm, Friday, 02'nd May 2025
BMRN reports encouraging first-quarter results. The company reiterates its financial guidance for 2025.
BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
08:35pm, Thursday, 01'st May 2025
While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare
BioMarin Pharmaceutical Inc. (BMRN) Q1 2025 Earnings Call Transcript
07:25pm, Thursday, 01'st May 2025
BioMarin Pharmaceutical Inc. (BMRN) Q1 2025 Earnings Call Transcript
BioMarin Pharmaceutical (BMRN) Beats Q1 Earnings and Revenue Estimates
06:20pm, Thursday, 01'st May 2025
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $1.13 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $0.71 per share a year ago.
BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance
04:05pm, Thursday, 01'st May 2025
First Quarter 2025 Total Revenues of $745 million (+15% Y/Y and +17% at Constant Currency Y/Y) First Quarter 2025 GAAP Diluted Earnings Per Share (EPS) of $0.95 (+107% Y/Y) First Quarter 2025 Non-GAAP
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
10:46am, Wednesday, 23'rd Apr 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
10:45am, Friday, 18'th Apr 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET
09:00am, Thursday, 17'th Apr 2025
SAN RAFAEL, Calif. , April 17, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a con
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q1 Release
11:06am, Wednesday, 16'th Apr 2025
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
6 Stocks With Clear Price Dislocations That I Purchased During Wall Street's Historic Volatility
03:06am, Friday, 11'th Apr 2025
The old idiom "blink, and you'll miss it" might be the best descriptor of the historic volatility we've witnessed on Wall Street over the trailing week, as of this writing on April 9.
Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report?
01:15pm, Thursday, 10'th Apr 2025
BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength?
09:20am, Thursday, 10'th Apr 2025
BioMarin (BMRN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength d
Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On
04:00pm, Wednesday, 09'th Apr 2025
Investors looking to maintain exposure to healthcare can invest in large-cap U.S.-based companies like UHS, BMRN and ABT.
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
02:25pm, Monday, 07'th Apr 2025
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and soli
3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN)
01:45pm, Monday, 07'th Apr 2025
BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market.
